Recent studies have highlighted that Activin A, a member of the transforming growth > factor-¦Â (TGF-¦Â) superfamily, may be involved in the regulation of osteoblastic > activity and in osteoclast differentiation. Therefore, we have investigated the > clinical significance of its circulating levels in patients with bone metastasis. > Activin A serum concentrations were determined, by a commercially available enzyme- > linked immunosorbent assay kit, in 72 patients with breast cancer (BC) or prostatic > cancer (PC) with (BM+) or without (BM-) bone metastases, in 15 female patients with > age-related osteoporosis (OP), in 20 patients with benign prostatic hypertrophy (BPH) > and in 48 registered healthy blood donors (HS) of both sex (25 female and 23 male). > Activin A serum concentrations were significantly increased in BC or PC patients as > compared to OP (P < 0.0001) or BPH (P = 0.045), respectively, or to sex matched HS (P > < 0.0001). Additionally, these levels resulted more elevated in PC patients as > compared to BC patients (P = 0.032). Interestingly, Activin A was significantly higher > in BM+ patients than in BM- patients (BC, P = 0.047; PC, P = 0.016). In BC patients, a > significant correlation was observed only between Activin A and number of bone > metastases (P = 0.0065) while, in PC patients, Activin A levels were strongly > correlated with the Gleason score (P = 0.011) or PSA levels (P = 0.0001) and, to a > lessen extent, with the number of bone metastases (P = 0.056). Receiver operating > characteristic curve (ROC) analysis showed a fair diagnostic accuracy of Activin A to > discriminate between BM+ and BM- patients (BC: AUC = 0.71 ¡À 0.09, P = 0.03; PC: AUC = > 0.73 ¡À 0.081, P = 0.005). These findings indicate that Activin A may be implicated in > the pathogenesis of bone metastasis. Therefore, this cytokine may be considered a > novel potential target for a more selective therapeutic approach in the treatment of > skeletal metastasis and may be also useful as additional biochemical marker of > metastatic bone disease. (C) Springer Science+Business Media B.V. 2006.
|Data di pubblicazione:||2006|
|Titolo:||Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.|
|Autori:||LETO, G; INCORVAIA, L; BADALAMENTI, G; TUMMINELLO, FM; GEBBIA, N; FLANDINA, C; CRESCIMANNO, M; RINI, GB|
|Tipologia:||Articolo su rivista|
|Citazione:||LETO, G., INCORVAIA, L., BADALAMENTI, G., TUMMINELLO, F.M., GEBBIA, N., FLANDINA, C., et al. (2006). Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. CLINICAL & EXPERIMENTAL METASTASIS, 23, 117-122.|
|Digital Object Identifier (DOI):||10.1007/s10585-006-9010-5|
|Appare nelle tipologie:||01 - Articolo su rivista|